IP Forecast: Fed. Circ. To Mull Narcan Patents

By Andrew Karpan (July 29, 2021, 9:31 PM EDT) -- Emergent BioSolutions' grip on its blockbuster opioid overdose medication Narcan is at stake in a patent case that reaches the Federal Circuit on Monday.

Adapt Pharma, an Emergent unit, is appealing a ruling from a New Jersey federal judge last June that found claims in four of its patents covering the drug's dosage were unpatentable, in light of how naloxone has been used in treating overdoses since the 1960s. The argument came from rival drugmaker Teva Pharmaceuticals USA Inc., which Adapt sued over Teva's efforts to market a generic version of the drug, which the U.S. Food and Drug Administration approved in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!